Trials / No Longer Available
No Longer AvailableNCT03123211
Expanded Access to Veliparib
- Status
- No Longer Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to veliparib prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria. EAP is also available for other indications where there is reasonable scientific basis for efficacy.
Detailed description
Expanded Access
Conditions
- Solid Tumors With Documented BRCA, BARD, or PALB or Other Acceptable DNA Mutations or Anomalies That Are Scientifically Sound
- Triple Negative Breast Cancer (TNBC)
- High Grade Serous Ovarian Cancer
- Patients Requiring Veliparib Suspension Formulation
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Veliparib | Veliparib will be administered orally. |
Timeline
- First posted
- 2017-04-21
- Last updated
- 2022-05-24
Source: ClinicalTrials.gov record NCT03123211. Inclusion in this directory is not an endorsement.